Probable RBD Associates with the Development of RLS in Parkinson’s Disease: A Cross-Sectional Study

Table 1

Comparison of clinical data between the PD with the RLS group and the PD with the non-RLS group.

Variables	PD with RLS ()	PD with non-RLS ()	Test value	value
Sex ( (%))			0.022	0.881^a
Male	14 (60.87)	76 (49.03)
Female	9 (39.13)	79 (50.97)
Age at presentation (yr, )			0.417^t	0.677^b
Age of PD onset (yr, )			0.182^t	0.856^b
Duration of PD (yr, M(QR))	5.00 (3.00)	3.00 (4.00)	1452.00	0.149
Side involved ( (%))			0.202^a	0.653^a
Unilateral	10 (43.48)	76 (49.03)
Bilateral	13 (56.52)	79 (50.97)
UPDRS III (M(QR))	22.00 (13.00)	18.00 (13.00)	1148.00	0.006
Hoehn and Yahr stage (M(QR))	2.00 (1.00)	2.00 (1.50)	1465.50	0.160
PRBD ( (%))				0.012^c
With PRBD	19 (82.61)	84 (54.19)
With non-PRBD	4 (17.39)	71 (45.81)
MMSE score (M(QR))	28.00 (4.00)	27.00 (3.00)	1644.50	0.545
HAMD score (M(QR))	12 (13.00)	7.00 (8.00)	1023.00	0.001
Daily LED (mg/day, M(QR))	437.50 (350.00)	300.00 (287.50)	962.00	≤0.001

PD = Parkinson’s disease; RLS = restless leg syndrome; UPDRS III = unified Parkinson’s disease rating scale III; PRBD = probable rapid eye movement sleep behavior disorder; MMSE = minimum mental state examination; HAMD = Hamilton depression scale; daily LED = daily levodopa equivalent dose. ^aFor test, ^bfor test, ^cfor Fisher’s exact test, and the rest is test; in PRBD, daily LED, UPDRS III, and HAMD scores.